Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection
Amount Raised
$270 Million
Round Type
Series C
BrisbaneBiotechnologyHealth CareScience And EngineeringVenture CapitalLife ScienceDescription
Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood draw, announced an oversubscribed $270 million Series C financing, bringing the company's total financing to over $500 million since the company’s launch. The proceeds will be used to accelerate the PREEMPT CRC™ clinical trial for Freenome’s blood test for colorectal cancer screening and precancerous lesion detection, advance a pipeline of blood tests for both the early detection and early intervention of additional cancers, and continue building the company’s proprietary multiomics platform. PREEMPT CRC is an FDA registrational study launched in May 2020 to support approval by the U.S. Food and Drug Administration (FDA) for the first front-line blood test to help the 45 million people who are currently not up-to-date on colorectal cancer screening guidelines in the U.S.
Quick answer
Freenome raised $270 Million in a Series C round, dated August 26, 2020. Freenome is based in Brisbane, California, United States.
- How much did Freenome raise?
- Freenome raised $270 Million in a Series C round on August 26, 2020.
- What does Freenome do?
- Freenome is a biotechnology company with a comprehensive multiomics platform for early cancer detection using a routine blood draw.
- Where is Freenome based and how big is it?
- Freenome is based in Brisbane, California, United States. Fundz records about 396 employees.
- Who are the decision-makers at Freenome?
- Fundz holds 1 contact at Freenome. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Venture Capital around the same time
Companies in the same sectors as Freenome that raised within 45 days of this round, from Fundz verified event records.
- SeLux Diagnostics, Inc. raised $814K (Seed) on October 1, 2020.
- Bond Biosciences raised $4.5M on September 14, 2020.
- Triumvira Immunologics Inc. raised $55M (Series A) on August 27, 2020.
- Triumvira Immunologics Inc. raised an undisclosed amount (Series A) on August 27, 2020.
- Mythic Therapeutics raised $19M on August 14, 2020.
- Mythic Therapeutics raised $4.7M on August 14, 2020.
Who to call at Freenome, and when
A new round usually means Freenome is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Freenome raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Freenome, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Freenome. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Freenome raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Freenome raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.